The year 2003 has been one for scientists to reflect on the progress made in the fields of genetics and genomics since the structure of DNA was solved some 50 years ago. It was with this in mind, and with palpable excitement over the publication of the draft sequence of the mouse genome, that the mouse genetics community gathered in Braunschweig in Lower Saxony for the 17th International Mouse Genome Conference. The historic city of Henry the Lion provided a fitting backdrop for reflection on how far we have come in such short a time and on the challenges and opportunities provided by our new found knowledge. For many reasons in addition to the available genome sequence, the mouse is consolidating its position as the preeminent animal model by which to study gene function. This has happened through targeted and genome-wide mutagenesis, the establishment of many murine models for human disease, and the development of the mouse as a system in which to study the incredible complexity of gene and protein interactions. Many of the tools available to carry out such research are newly emerging and provided the basis for much of the discussion and debate during the course of the Conference.
The meeting began with Ken Paigen (Jackson Laboratory, USA) presenting the annual Verne Chapman Memorial lecture in memory of one of the leading lights in mouse genetics. Ken instituted his own ''Michelin Star'' system for scientific discovery, trying to place in perspective the recent developments in the field with more distant, but no less important, advances in our understanding. Fittingly, 4 and 5 star awards were hard to come by. It was noted that the invention of the scientific method by Roger Bacon in the 13th century was instrumental in furthering our knowledge, but equally high on his list were some seemingly humble events of scientific history. These included the invention of the microscope and the thermometer; acknowledgment of the contribution that technology makes to advancing our wider understanding of the world. Ken alluded to the ''fits and starts'' which in the past have characterized scientific endeavor, in many cases due to the constraints of either stilted conceptual thought or technological impediments to progress. Significantly though, he suggested that biologists are now enjoying a period when we are limited by neither and, for the time being at least, we should enjoy the fruits of both a golden technological age and a revolution in how we think about genes, genomes, and their implications for human disease and development. While he honorably declined to rate exactly how our own ''genomic revolution'' stood in comparison to past paradigm shifts, he captured for many in the audience the excitement of the times. The first evening of the meeting concluded with a memorable rendition of Carmina Burana from the Braunschweig Cathedral Choir, proving beyond question that the delegates were at ease with cultures other than the bacterial.
The Genome at large: big science for everyone Several sessions of the meeting were devoted to reports of our increased knowledge of the mouse genome: its expression, organization, and the development of resources and technologies to help us understand it. Several talks touched on the large-and small-scale structure of the genome and the interstrain variations now apparent in the sequence itself. Duplications of relatively large (>10 kb) genome blocks were considered in a very recently released build of the genome (NCBI Build 30) in which apparent duplication is significantly lower than in human assemblies (Deanna Church, NCBI, USA).
Many duplications were noted to be in contigs and BAC clones which are currently not integrated into the draft sequence. A comparison of the finished sequence indicated that the actual level of duplication was somewhat higher (though still less than in humans) and that the whole genome shotgun assembly has lost many duplicated contigs. At a base pair level, the zoo of mouse SNPs is growing ever larger, with efforts to genotype 10,000 SNP-based markers in 48 strains of the JAX phenome project (Matthew Peltcher, Novartis Research Foundation, USA). This resource will undoubtedly prove valuable for those seeking to map mutant phenotypes and elusive QTLs in the genome.
Indeed one session of the meeting was devoted to QTL analysis, an area in which real progress has been made in the last few years, both in identifying loci and the functional polymorphisms which underlie them. Several presentations focused on the identification of QTLs using a combination of candidate gene analysis and the generation of congenic mouse strains. An excellent example of this was given by Konrad Noben-Trauth (NIDCD/NIH, USA) who identified, using positional cloning, a functional polymorphism in cadherin 23 which is associated with polygenic inheritance of age-related hearing loss (AHL) (Noben-Trauth et al. 2003 ). This polymorphism results in skipping of exon 7 which leads to an increased susceptibility to AHL. However, this polymorphism alone does not cause the phenotype; it is dependent on the presence of additional genetic factors such as a null allele of Atp2b2, which is an important regulator of Ca + levels in the stereocilia of the ear. Beverley Paigen (Jackson Laboratories, USA) presented an interesting overview on the known loci that modulate mouse HDL cholesterol metabolism. Intriguingly, 22 out of 25 human QTLs have syntenic mouse QTL suggesting that the same genes may underlie the respective phenotypes. This reiterates the power of the mouse genetics for analyzing and identifying genes for common human traits. Her laboratory tackles the difficult task of identifying the causative genes by statistically combining mouse crosses, the use of extensive haplotype analysis, and candidate gene sequencing. This approach has led to the characterization of Abca1 and Apoa2 alleles that affect HDL levels.
One possible strategy to identify QTLs that have small effects on phenotype is through the use of mouse heterogenous stock (HS) strains. Results using this strategy were presented by Richard Mott and Binnaz Yalcin (Wellcome Trust Centre for Human Genetics, UK). The HS mice were derived from eight different mouse inbred strains which were interbred for numerous generations (Mott and Flint 2002 ).
This approach enables the identification of small candidate regions for QTLs that contain only a few genes. A program has been started to analyze 2000 HS mice for a wide variety of phenotypic traits. Currently, phenotypes have been determined for 1000 mice and completion of the remainder is expected this year. The animals will also be genotyped at 6000 SNP loci to enable resolution of their fine genetic mosaic. These HS strains have already been used to fine map an anxiety susceptibility QTL to a 0.8-cM interval Chromosome 1 which contains only 9 genes.
Turned on by gene expression
Understanding how genes are globally expressed in ''resting'' tissues and during development, disease, and infection is now a reality given the development of array technologies and a more complete knowledge of the mouse transcriptome. Efforts to develop a microarray platform that will allow the analysis of the expression pattern of all genes in both the human and mouse genomes are well underway (Mark Carter, NIH/NIA, USA). One of the highlights of the meeting described the assessment of the expression of the transcriptome in various tissues from both human and mouse (Tim Wiltshire, Novartis Research Foundation, USA). High-density oligonucleotide arrays of around 35,000 mouse and human transcripts have been examined in more than 60 and 80 tissues, respectively. More importantly though, these data have been integrated with genome sequence as part of the GexView database, meaning it is now possible to assess gene expression in a variety of tissues in a specific region of the genome (http:// expression.gnf.org). Such technology will doubtless prove invaluable for those of us faced with large candidate intervals populated by many genes, but it has also allowed some of the first studies of gene expression at a genome level. Perhaps not surprisingly it turns out that many neighboring genes are coordinately regulated. However, there is increasing evidence that this coregulation cannot always be explained by shared promoters or local duplication events. We await with great interest the results of further studies addressing the effects of higher-order controls on gene expression.
When a gene is expressed can obviously tell us a great deal about its possible physiological and developmental roles. An excellent example of this was presented by Dr. Sally Camper (University of Michigan, USA) who has focused intensive efforts on cataloging gene expression over a 48-h period of normal and mutant pituitary development. By uti-lizing CAP trapping technology, Dr. Camper's group, in collaboration with RIKEN Laboratories, developed several embryonic pituitary-specific cDNA libraries to examine gene expression changes over this brief window of development. Impressively, these libraries are among the most ''unique'' of the entire RI-KEN set in terms of the diversity and novelty of the genes represented. For example, the library includes representatives of more than 700 transcription factors including many of the Hox genes. Around 20% of the clones in the library represent previously unidentified transcripts. These libraries have proved to be an invaluable resource to study comparative gene expression as well as developmentally regulated transcriptional alterations. They also highlight the importance of carefully studying tissue-specific gene expression at crucial developmental stages. The potential complexity of transcriptional and translational control was highlighted by Hiroaki Kitano (Sony Computer Science Laboratories, Japan). Dr. Kitano presented an introduction to the rapidly emerging field of systems biology and the important role that it will play in organizing and interrelating the information gleaned from expression analysis, protein interactions, and our increased understanding of genome structure and sequence.
Mutagenizing the genome
One of the major challenges posed by the wealth of mouse sequence information is to begin to understand what it is that all of the genes do. In part, this can be addressed by better characterizing their expression and how it changes in response to developmental events and disease states. However, the gold standard in many respects is to inactivate the gene. Several genome-wide approaches have been taken to achieve this goal. The first is to utilize genetrapping experiments to generate a range of targeted clones suitable for the subsequent generation of null animals. This approach has been taken by a variety of private and public programs and delegates were briefed on the most recent results deriving from the German Gene Trap Consortium (Thomas Floss, GSF, Germany) which has characterized more than 11,000 integration sites in ES cells using a variety of targeting vectors. Although the number of actual mouse lines reconstituted from this resource to date is low (30), the phenotypes observed were comparable with conventional gene-targeting experiments. The potential to use a forward genetic approach to assess the consequences of gene traps in ES cells by microarray analysis was also discussed (Derek Symula, Wadsworth Centre, USA). Although preliminary, it seems that some parallels can be drawn between gene expression changes observed in targeted ES cells and tissues from adult mice, although the power with which we can predict resulting phenotypes is currently limited. A second approach to global mutagenesis involves the use of germline mutagens, particularly ENU, to generate mutant mice. The conference heard a range of reports on the increasing success of these approaches but the majority of discussion focused on how to get the most out of these screens. One of the take-home messages was that a mutagenesis screen is only as good as the phenotyping regime which is applied to it. This realization has seen the rise of several phenotyping collaborations and schemes. Eumorphia (http:// www.eumorphia.org) represents a Europe-wide collaboration that aims to standardize phenotypic tests for a variety of different physiological parameters and which extends to the levels of animal care, nutrition, and habitat. An example of a fully integrated phenotyping center was presented from the German Mouse Clinic (GMC; Hrabe de Angelis GSF/Germany). The GMC is a collaboration between 12 laboratories of different phenotyping areas working under one roof. Over 200 parameters are measured on every single mouse in a standardized way (http:// www.mouseclinic.de). One of the most pertinent problems facing the mouse community which will be addressed by these consortia is to establish good baseline physiological measurements for a variety of mouse strains. These will subsequently allow legitimate comparison of the phenotypes arising from mutagenesis screens worldwide.
The impact that technology can have on increasing our understanding of mouse phenotypes was highlighted by several talks. Mark Henkleman (Hospital for Sick Children, Canada) elegantly detailed recent advances in imaging platforms which can potentially be used for the assessment of physiology and pathology. These include the use of ultrasound to study cardiac defects, optical projection tomography to study comparative anatomy, and, perhaps most impressive of all, the use of magnetic resonance imaging to generate high-resolution images of the adult mouse. Advances in the software used to analyze the information generated from MRI scans means that it is now possible to gain large amounts of information about aberrant phenotypes. He raised the problem, though, of how to compare the results of such investigations. It was pointed out, for example, that while it was possible to say that renal vascular trees from different inbred strains are ''similar,'' the complexity of the structure means it is hard to compare them directly and this raises fundamental questions about what we consider to be ''anatomical equivalents.'' In many ways this prob-lem is the same as that currently being addressed by the various phenotyping consortia and reinforces the importance of establishing what we consider to be ''normal'' in the mouse. A later talk by Cory Brayton (Baylor College of Medicine, USA) raised the more obvious perils that subclinical infections and diseases in mouse colonies can have for the assessment of mutant ''phenotypes.'' She highlighted the fact that any accurate assessment of mutant pathology should involve a thorough knowledge of the strainspecific phenotypes which are often apparent irrespective of genetic manipulation.
Delta/Notch signaling
Ultimately it will be the combination of knowledge gained from large-scale studies and smaller but more focused approaches that will facilitate progress in the understanding of complex signaling pathways. A nice example of this was the results presented in three talks concerning the elucidation of the Notch/Delta pathway. Christine Machka (GSF, Germany) used microarray analysis and two-dimensional gel electrophoresis to identify novel Delta/Notch targets. Array analysis identified 53 genes that were differentially expressed between wild-type and Delta null mouse embryos. Forty-six genes have been identified that are up-or downregulated in mutant embryos and about half of these are of unknown function. Twodimensional electrophoresis revealed differentially expressed proteins. Moderate differences were noted in expression changes between the identified genes and proteins but only 25% shared the same tendency on the chip and 2D gel experiments. These results highlight the need for rigorous confirmation and followup analysis of large-scale screens. Julius Barsi (University of Texas, USA) showed that the ubiquitination of Delta is necessary for the proper development of embryonic neuroepithelial stem cells. Both Mindbomb (Mib1, a Ring finger E3 ligase) and neuralized (Neur) proteins are directly responsible for the ubiquitination of Delta. While Neur null animals survive gestation, Mib1 null mice die at 10.5 dpc and lack Notch/Delta pathway function. The mouse phenotype is characterized by premature differentiation of neural epithelial cells accompanied by a loss of structural integrity of the neuroepithelium. Additionally, the study noted the subsequent apoptotic death of these premature newborn neurons. It was hypothesized that excess Delta1 in Mib1 null mice leads to disruption of the Notch/Delta pathway, followed by mass neural differentiation at 9.5 dpc due to a lack of lateral inhibition. It is thought that the increased levels of DAPK (death-associated protein kinase) in Mib1 null animals results in the deregulation of apoptosis and the observed death of the newly differentiated neurons. A different approach to elucidate the signaling role of Delta was described by Sabine and Pfister (GSF, Germany). By using yeast two hybrid screens with the cytoplasmic region of Delta as bait, they identified Acvrinp1, a member of the MAGUK protein family, as an interacting protein. Acvrinp1 shows a partly overlapping but distinct expression pattern to Delta and has altered expression patterns in the null mice (Pfister et al. 2003) . These results suggest that Delta, in addition to Notch, has a role is cell signaling. The next few years promise to be very exciting as we are gaining a better undemanding of the complexities and roles of the Delta/Notch pathway.
The mutant mouse as a model of human disease
One of the main reasons for the preeminence of the mouse as a mammalian model derives from its potential to phenocopy human disease. As a consequence, it is possible to gain a far more detailed understanding of the physiology underlying disease by studying its mouse model. This principle is no better illustrated than in studies of the mouse as a model of deafness. Karen Steel (Sanger Institute, UK) presented recent work on the genetics and physiology of Usher syndrome, a heterogeneous human disorder about which our understanding has been greatly enhanced by the existence of several mouse mutant models of the disease. Indeed, in several instances the elucidation of genetic defects in the mouse has preempted the discovery of analogous mutations in human patients. Professor Steel discussed physiological and anatomical studies of waltzer mice, with mutations of cadherin 23, and shaker1 mice, who harbor a defect in myosin 7a. In these animals the normally exquisite structure and crosslinking of the hair cells of the inner ear is disrupted. There are, however, subtle differences in the structure of the hair cells which turn out to reflect the different role that these proteins play in maintaining the contacts between these cells. These differences are thought to underlie the different reactions of the two mutants to noise-induced hearing loss to which waltzer mice are susceptible and shaker1 mice are resistant. Studies of the susceptibility of these mice to retinopathies characteristic of human Usher syndrome reveal that these alleles are in fact protective against light-induced retinal damage, suggesting that the two proteins are involved in photoreceptor cell activation. These animal models have proven invaluable in furthering our understanding of the structural defects that underlie human Usher syndrome and how they con-tribute to the phenotypes seen in both mouse and man.
In another highlight, Bill Dove (University of Wisconsin, USA) discussed the mouse as a model of gastrointestinal cancer. The study of this complex disease introduced the role of both gatekeeper genes and cell signaling pathways in the development of cancerous phenotypes. The basis of the studies described was the multiple intestinal neoplasia (Min) mouse, an ENU-induced nonsense allele of the ''gatekeeper'' gene Apc. Mice heterozygous for the Min mutation develop intestinal adenomas and are an excellent model for human gastrointestinal cancer. Inactivation of the remaining wild-type Apc allele can result from either somatic recombination, mutation, or through epigenetic silencing. Study of tumors in these animals requires cell markers to characterize the neoplastic phenotype and delegates were presented with a range of different marker types, including those offering cellular resolution (such as retroviral gene traps and tagged knockouts) as well as genes identified from whole-tissue-based screens such as cDNA subtraction and expression arrays. Some of these genes, such as clusterin, identify novel markers with the potential diagnostic use in human disease (Chen et al. 2003) . The importance of good biomarkers was highlighted by studies of the phenotype of the Min mutation on different genetic backgrounds which found that location of tumors along the GI tract was altered. By studying tumor number and progression in Min heterozygotes, which also harbored Robertsonian chromosomal translations, the researchers were able to gain further insight into the basis of tumor formation. The altered karyotype of these mice reduced levels of somatic recombination which led to a concomitant decrease in the numbers of tumors observed in these animals but not the proliferation rate of those tumors present (Haigis and Dove 2003) . These results argue that the majority of tumors in these animals derive from inactivation of the functional Apc allele by homologous somatic recombination. The talk also highlighted the importance of identifying modifiers of disease phenotype such as p53, Cdkn1b, and Pla2g2a. There is increasing evidence that studies of this type can translate well to the study of human colon cancer, although the obvious differences in physiology between the two species means that careful validation of the results derived is required.
A particular focus of the meeting was the use of the mouse as a model and tool to study immunology and there were several presentations discussing the results of screens designed specifically to dissect immune function in the mouse. Bruce Beutler (The Scripps Institute, USA) presented an excellent example of the potential success which can arise from a well-controled and phenotypically directed recessive ENU mutagenesis screen. The research he presented focused on the Toll family of receptors, which bind to components of invading microbes and serve as triggers for the host innate immune response. His group has utilized in vitro and in vivo assays to elegantly dissect the role of various proteins involved in lipopolysaccharide (LPS) and double-stranded RNA (dsRNA) response in the mouse, from their 1 reception on the surface of cells through the signal transduction pathway to the nucleus. A novel ENU-induced recessive mutant known as Lps2 has been identified and was shown to result from a mutation in an intracellular adapter protein called Trif (Hoebe et al. 2003b ). 2 Trif is required for signaling from several of the toll-like receptors, in particular, Toll3 (Tlr3) and Toll4 (Tlr4). The identification of mutations in Trif also provided a means by which to study the mechanism by which adjuvants such as LPS and dsRNA activate the immune response. This process results in the upregulation of a variety of costimulatory molecules including many cytokines and particularly interferon beta, which signals through the type 1 interferon receptor. Subsequent studies showed that LPS-induced signaling occurred solely through the Tlr4/Trif system but that activation of the dsRNA response was only partially mediated through Tlr3/Trif (Hoebe et al. 2003a ). 3 Because the upregulation of costimulatory molecules through both pathways is mediated solely through the type 1 interferon receptor pathway, it implies that a paracrine or autocrine loop regulates this activation and that a Trif independent pathway must mediate some aspects of the cellular response to dsRNA.
The future
The 17th International Mouse Genome Conference presented a first glimpse of the benefits that are beginning to emerge from the availability of the genome sequence and the development of techniques, technology, and resources with which to utilize it. It certainly also highlighted the importance of the mouse as a model by which we can learn more about our own biology. Meetings in the years to come are certain to encapsulate highlights of this endeavor. The IMGC is held yearly at venues in Europe, America, and Asia and is organized by the Mammalian Genome Society. New members are welcome and details can be obtained from the organization secretary Darla Miller (MillerDR@ornl.gov) or from the IMGS website (www.imgs.org). Conference abstracts are also available at this address. The Society extends an open invitation to attend the next IMGC meeting which will be held in Seattle 18-23 October 2004.
